Cargando…

Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine

The ongoing pandemic of coronavirus (CoV) disease 2019 (COVID-19) continues to exert a significant burden on health care systems worldwide. With limited treatments available, vaccination remains an effective strategy to counter transmission of severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuyama, Wakako, Shifflett, Kyle, Pinski, Amanda N., Griffin, Amanda J., Feldmann, Friederike, Okumura, Atsushi, Gourdine, Tylisha, Jankeel, Allen, Lovaglio, Jamie, Hanley, Patrick W., Thomas, Tina, Clancy, Chad S., Messaoudi, Ilhem, O’Donnell, Kyle L., Marzi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749411/ https://www.ncbi.nlm.nih.gov/pubmed/35012339 http://dx.doi.org/10.1128/mbio.03379-21

Ejemplares similares

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine
por: Furuyama, Wakako, et al.
Publicado: (2021)

Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model
por: O'Donnell, Kyle L., et al.
Publicado: (2021)

Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model
por: O’Donnell, Kyle L., et al.
Publicado: (2021)

VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

Optimization of single dose VSV-based COVID-19 vaccination in hamsters
por: O’Donnell, Kyle L., et al.
Publicado: (2021)

Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
por: Suder, Ellen, et al.
Publicado: (2018)

Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease
por: Marzi, Andrea, et al.
Publicado: (2021)

Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus
por: Mire, Chad E., et al.
Publicado: (2013)

The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway
por: Furuyama, Wakako, et al.
Publicado: (2021)

Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection
por: Menicucci, Andrea R., et al.
Publicado: (2019)

Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
por: Marzi, Andrea, et al.
Publicado: (2015)

A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades
por: Furuyama, Wakako, et al.
Publicado: (2020)

Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates
por: Mire, Chad E., et al.
Publicado: (2014)

Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease
por: Monath, Thomas P., et al.
Publicado: (2023)

Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates
por: Geisbert, Thomas W., et al.
Publicado: (2008)

Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques
por: Marzi, Andrea, et al.
Publicado: (2023)

Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates
por: Mire, Chad E., et al.
Publicado: (2012)

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine
por: O'Donnell, Kyle L., et al.
Publicado: (2023)

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection
por: Marzi, Andrea, et al.
Publicado: (2016)

Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation
por: Marzi, Andrea, et al.
Publicado: (2019)

Long-Term Single-Dose Efficacy of a Vesicular Stomatitis Virus-Based Andes Virus Vaccine in Syrian Hamsters
por: Prescott, Joseph, et al.
Publicado: (2014)

Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus
por: Prator, Cecilia A., et al.
Publicado: (2023)

Transcriptional Analysis of Infection With Early or Late Isolates From the 2013–2016 West Africa Ebola Virus Epidemic Does Not Suggest Attenuated Pathogenicity as a Result of Genetic Variation
por: Maroney, Kevin J., et al.
Publicado: (2021)

Distinct transcriptional responses to fatal Ebola virus infection in cynomolgus and rhesus macaques suggest species-specific immune responses
por: Pinski, Amanda N., et al.
Publicado: (2021)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses
por: Safronetz, David, et al.
Publicado: (2015)

Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates
por: Bhatia, Bharti, et al.
Publicado: (2023)

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
por: Mire, Chad E., et al.
Publicado: (2019)

Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection
por: Fletcher, Paige, et al.
Publicado: (2023)

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus
por: Matassov, Demetrius, et al.
Publicado: (2015)

Evaluating Temperature Sensitivity of Vesicular Stomatitis Virus–Based Vaccines
por: Stein, Derek R., et al.
Publicado: (2019)

Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector
por: Clarke, David K., et al.
Publicado: (2006)

Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector
por: Liu, Guodong, et al.
Publicado: (2021)

Acute SARS-CoV-2 infection is associated with an increased abundance of bacterial pathogens, including Pseudomonas aeruginosa in the nose
por: Rhoades, Nicholas S., et al.
Publicado: (2021)

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
por: Domi, Arban, et al.
Publicado: (2018)

High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission
por: Morozov, Igor, et al.
Publicado: (2021)

Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials
por: Cooper, Christopher L., et al.
Publicado: (2022)

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
por: Fathi, Anahita, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tkv81e58hgb8urrdajv2j9rpvs